Quantification of Expression of Antigens Targeted by Antibody-Based Therapy in Chronic Lymphocytic Leukemia
Open Access
- 1 December 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 140 (6) , 813-818
Abstract
Objectives. Anti-CD20 (rituximab), anti-CD52 (alemtuzumab), anti-CD22 (BL22, HA22), and anti-CD25 (Oncotac) are therapeutic options that are the mainstKeywords
This publication has 31 references indexed in Scilit:
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab PasudotoxClinical Cancer Research, 2011
- Variables in the quantification of CD4 in normals and hairy cell leukemia patientsCytometry Part B: Clinical Cytometry, 2010
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2010
- Early treatment of high‐risk chronic lymphocytic leukemia with alemtuzumab and rituximabCancer, 2008
- Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in‐situ hybridization in 510 patientsBritish Journal of Haematology, 2008
- Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemiaCytometry Part B: Clinical Cytometry, 2007
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaLeukemia, 2007
- Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B‐cellsCytometry Part B: Clinical Cytometry, 2006
- Malignancies induced by chlorambucilCancer Treatment Reviews, 1984